

IN THE CLAIMS:

Claims 1-9. (Canceled)

Claim 10. (Original) A method of inhibiting the adhesion of integrin expressing cells to vitronectin comprising exposing said cells to contortrostatin so that contortrostatin binds to the integrin.

Claim 11. (Original) A method of inhibiting the adhesion of integrin expressing cells to vitronectin comprising exposing said cells to contortrostatin so that contortrostatin binds to the integrin.

Claim 12. (Original) A homodimeric disintegrin comprising an amino acid sequence which is at least 90% percent identical to amino acid numbers 419 to 483 of SEQ ID NO: 2, wherein said contortrostatin amino acid sequence (i) binds to integrin $\alpha v\beta 5$ and (ii) induces $\alpha v\beta 3$ -mediated tyrosine phosphorylation of CAS and FAK in tumor cells.

Claim 13. (Original) The homodimeric disintegrin of claim 12 having an amino acid sequence selected from the group consisting of :

- (a) amino acid numbers 419 to 483 of SEQ ID NO: 2;
- (b) an amino acid sequence at least 95% identical to (a) as determined by FASTA or BLAST using default opening and gap penalties and a default scoring matrix.

Claim 14. (Original) A pharmaceutically acceptable composition comprising a pharmaceutically acceptable carrier and a homodimeric disintegrin according to claim 12.